Press release Financial tableOrganic revenue growth of +2.3% supported by both segments Care Delivery and Care EnablementOperating income1 and operating income margin1 increase driven by Care EnablementAdditional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings target rangeFurther divestitures closed as execution of portfolio optimization program continuesNet financial debt and net leverage ratio further improvedFY 2024 outlook confirmed .

新闻稿财务表有机收入增长2.3%，这得益于护理服务和护理支持运营收入1和运营收入利润率1的增长，这是由于护理支持实现了额外的FME25节约5700万欧元，有望达到全年节约目标范围的上限。随着投资组合优化计划的继续实施，资产剥离进一步结束净财务债务和净杠杆率进一步提高2024财年前景得到证实。

Bad Homburg (July 30, 2024) – “In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proof point for the operational turnaround as we remain focused to deliver on our targets”, said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG.

巴德·洪堡（2024年7月30日）——“在第二季度，我们在执行战略计划和公司转型的同时，进一步改善了财务业绩。这一季度是运营转型的另一个重要证据，因为我们仍然专注于实现目标”，费森尤斯医疗保健公司首席执行官海伦·吉萨表示。

“Our operating income margin progressed toward our 2025 margin target band, as Care Enablement increased its profitability. In Care Delivery, U.S. same market treatment growth improved sequentially despite continued elevated mortality. In both segments, we accelerated FME25 savings against plan and are now on track to reach the upper end of our FME25 savings target range for 2024.” Giza added: “In light of the developments in the first half year, we confirm our financial outlook for the full year 2024.”.

“我们的营业收入利润率朝着2025年利润率目标区间发展，因为护理支持提高了其盈利能力。在护理服务方面，尽管死亡率持续升高，但美国同一市场治疗的增长仍在继续提高。在这两个领域，我们都加快了FME25的计划储蓄，现在正朝着2024年达到FME25储蓄目标范围上限的目标迈进。”吉萨补充道：“鉴于上半年的发展，我们确认了2024年全年的财务前景。”。

Key figures (unaudited) Q2 2024EUR mQ2 2023EUR mGrowthyoyGrowthyoy, ccH1 2024EUR mH1 2023EUR mGrowthyoyGrowthyoy, ccRevenueon outlook base14,7664,7434,8254,741 -1% -2%0%9,4919,5659,5299,3600% 0%+2%Operating incomeon outlook base1425433357400+19% +21%+8%671849618738+9% +10%+15%Net income2on outlook base1187207140176+33% +34%+18%258405227322+14% +15%+26%Basic EPS (EUR)on outlook base10.640.700.480.60+33% +34%+18%0.881.380.771.10+14% +15%+26%yoy = year-on-year, cc = at constant currency, EPS = earnings per share.

主要数字（未经审计）2024Q2欧元mQ2 2023EUR MGROwthygrowthy，ccH1 2024EUR mH1 2023EUR MGROwthygrowthy，ccRevenueon outlook Base147474348254741-1%-2%0%94919565952993600%0%+2%0%1425433357400+19%+21%+8%671849618738+9%+10%+15%2%2基于10.640.700.480.60+33%+34%+18%0.881.380.771.10+14%+15%+26%的预期，基本每股收益（欧元）同比增长26%，cc=不变货币，每股收益=每股收益。

Focused execution against the strategic plan

针对战略计划集中执行

In the second quarter, the FME25 transformation program continued its momentum, delivering EUR 57 million additional sustainable savings while related one-time costs amounted to EUR 40 million. With the progress in the second quarter, Fresenius Medical Care is on track to reach the upper end of the targeted additional sustainable savings range of EUR 100 to 150 million by year end 2024, totaling to EUR 650 million by year end 2025..

。随着第二季度的进展，费森尤斯医疗保健公司有望在2024年底达到目标额外可持续储蓄范围的上限，即1亿至1.5亿欧元，2025年底达到6.5亿欧元。。

Moreover, Fresenius Medical Care is executing its portfolio optimization plan to exit non-core and dilutive assets. During the second quarter, the company closed the divestment of Cura Day Hospitals Group, Australia, and of its dialysis clinic networks in Chile, Ecuador, Sub-Saharan Africa and Turkiye.

此外，费森尤斯医疗保健公司正在执行其投资组合优化计划，以退出非核心和稀释性资产。在第二季度，该公司完成了对澳大利亚库拉日间医院集团及其在智利、厄瓜多尔、撒哈拉以南非洲和土耳其的透析诊所网络的撤资。

The divestitures of clinic operations in Curacao, Guatemala and Peru were closed in July. Special items associated with portfolio optimization amounted to negative EUR 15 million in the second quarter..

库拉索岛、危地马拉和秘鲁的诊所业务剥离已于7月关闭。与投资组合优化相关的特殊项目在第二季度为负1500万欧元。。

All transactions that are currently signed as part of Fresenius Medical Care’s portfolio optimization plan are estimated to negatively impact operating income by around EUR 250 million in the full year 2024 and will be treated as special items. These transactions are expected to generate cash proceeds of around EUR 650 million upon closing, thereof approx.

据估计，目前作为费森尤斯医疗保健投资组合优化计划一部分签署的所有交易将在2024年全年对营业收入产生约2.5亿欧元的负面影响，并将被视为特殊项目。这些交易预计在交割时产生约6.5亿欧元的现金收益，其中约。

EUR 500 million have been received by the end of the second quarter..

截至第二季度末，已收到5亿欧元。。

Revenue development impacted by execution against portfolio optimization plan

投资组合优化计划执行情况对收入发展的影响

Revenue decreased by 1% to EUR 4,766 million in the second quarter (-2% at constant currency, +2% organic). Revenue on outlook base1 grew by 0.1% compared to prior year. Divestitures realized during 2023 and during the second quarter 2024 negatively impacted the revenue development.

第二季度收入下降1%，至47.66亿欧元（按固定货币计算为2%，有机货币为2%）。outlook base1的收入比上年增长了0.1%。2023年和2024年第二季度实现的资产剥离对收入发展产生了负面影响。

Care Delivery revenue decreased by 3% to EUR 3,771 million (-3% at constant currency, +2% organic) and by 1% on outlook base1.

。

In Care Delivery U.S., revenue increased by 1% (0% at constant currency, +1% organic) and by 1% on outlook base1. A growing value-based care business, reimbursement rate increases and a favorable payor mix had a positive impact. Effects from elevated mortality continued to weigh on U.S. same market treatment growth in a year-over-year comparison, while sequential trends remain encouraging.

在美国的护理服务中，收入增长了1%（固定货币为0%，有机物为+1%），前景为1%。基于价值的护理业务不断增长，报销率提高以及有利的付款人组合产生了积极影响。与去年同期相比，死亡率上升的影响继续影响美国同市场治疗的增长，而连续趋势仍然令人鼓舞。

Adjusted for the exit from less profitable acute care contracts (-0.2%), U.S. same market treatment growth came in flat (-0.1%)..

由于退出利润较低的急症护理合同（下降0.2%），美国同一市场治疗增长持平（下降0.1%）。。

In Care Delivery International, revenue decreased by 18% (-18% at constant currency, +3% organic) and by 12% on outlook base1. This negative development was strongly driven by divestments closed during the second quarter and partially offset by organic growth. International same market treatment growth was positive at 1.9%..

在Care Delivery International，收入下降了18%（-固定货币为-18%，有机物为+3%），前景为12%1。这种负面发展受到第二季度结束的撤资的强烈推动，部分被有机增长所抵消。国际同市场治疗增长率为1.9%。。

Care Enablement revenue grew by 3% to EUR 1,363 million (+3% at constant currency, +3% organic) and by 3% on outlook base1 as positive pricing momentum continues.

随着积极的定价势头持续，支持护理的收入增长了3%，达到13.63亿欧元（按固定货币计算为3%，有机物为3%），在展望基础上增长了3%。

Within Inter-segment eliminations, revenue for products transferred between the operating segments at fair market value decreased by 1% to a deduction of EUR 368 million (-2% at constant currency).3

在部门间冲销中，以公平市场价值在经营部门之间转移的产品收入减少了1%，减少了3.68亿欧元（按固定货币计算为2%）

In the first half, revenue remained virtually unchanged at EUR 9,491 million (0% at constant currency, +3% organic) and on outlook base1 increased by 2%. Care Delivery revenue decreased by 1% to EUR 7,559 million (0% at constant currency, +4% organic), with Care Delivery U.S. growing by 2% (+2% at constant currency, +4% organic) and Care Delivery International decreasing by 14% (-11% at constant currency, +3% organic).

上半年，收入几乎保持不变，为94.91亿欧元（按固定货币计算为0%，有机物为+3%），展望1增长了2%。护理服务收入下降1%，至75.59亿欧元（固定货币为0%，有机物为4%），美国护理服务收入增长2%（固定货币为2%，有机物为4%），国际护理服务收入下降14%（固定货币为-11%，有机物为3%）。

Care Enablement revenue increased by 1% to EUR 2,660 million (+2% at constant currency, + 2% organic). Inter-segment eliminations decreased by 1% to a deduction of EUR 728 million (0% at constant currency)..

护理支持收入增长1%，达到26.6亿欧元（按固定货币计算为2%，有机货币为2%）。部门间冲销减少了1%，减少了7.28亿欧元（以固定货币计算为0%）。。

Operating margin improvement driven by Care Enablement

运营利润率的提高得益于护理支持

Operating income increased by 19% to EUR 425 million in the second quarter (+21% at constant currency), resulting in a margin of 8.9% (Q2 2023: 7.4%). Operating income on outlook base1 increased by 8% to EUR 433 million, resulting in a margin of 9.1% (Q2 2023: 8.4%). Divestitures realized during the second quarter had a neutral effect on operating income..

。基于前景的营业收入1增长了8%，达到4.33亿欧元，利润率为9.1%（2023年第二季度：8.4%）。第二季度实现的资产剥离对营业收入产生中性影响。。

Operating income in Care Delivery decreased by 14% to EUR 332 million (-13% at constant currency), resulting in a margin of 8.8% (Q2 2023: 9.9%). Operating income on outlook base1 decreased by 7%, resulting in a margin1 of 9.9% (Q2 2023: 10.6%). In-line with expectations, the development was mainly driven by higher personnel expenses and inflationary cost increases.

护理服务的营业收入下降了14%，降至3.32亿欧元（按不变货币计算为13%），利润率为8.8%（2023年第二季度：9.9%）。基于前景的营业收入1下降了7%，利润率为9.9%（2023年第二季度：10.6%）。与预期一致，这一发展主要是由于人员支出增加和通货膨胀成本增加。

Business growth and savings from the FME25 program contributed positively to the earnings development..

FME25计划带来的业务增长和储蓄对收益发展做出了积极贡献。。

Operating income in Care Enablement strongly increased to EUR 68 million (Q2 2023: EUR 2 million), resulting in a margin of 5.0% (Q2 2023: 0.1%). Operating income on outlook base1 quadrupled compared to prior year, resulting in a margin1 of 5.1% (Q2 2023: 1.3%). The strong increase was driven by business growth and savings from the FME25 program, compensating inflationary cost increases and a negative impact from foreign currency transaction..

护理支持的营业收入大幅增加至6800万欧元（2023年第二季度：200万欧元），利润率为5.0%（2023年第二季度：0.1%）。基于前景1的营业收入比上年增长了四倍，利润率为5.1%（2023年第二季度：1.3%）。这一强劲增长是由业务增长和FME25计划节省的资金推动的，弥补了通货膨胀成本的增加和外汇交易的负面影响。。

Operating income for Corporate amounted to EUR 30 million (Q2 2023: EUR -25 million). Operating income on outlook base1 amounted to EUR 0 million (Q2 2023: EUR -13 million).

公司营业收入为3000万欧元（2023年第二季度：2500万欧元）。展望基础1的营业收入为0百万欧元（2023年第二季度：1300万欧元）。

In the first half, operating income increased by 9% up to EUR 671 million (10% at constant currency), resulting in a margin of 7.1% (H1 2023: 6.5%). Divestitures realized during the first half had a slightly positive impact on operating income. Operating income on outlook base1 increased by 15% up to EUR 849 million, resulting in a margin of 8.9% (H1 2023: 7.9%).

上半年，营业收入增长9%，达到6.71亿欧元（以不变货币计算为10%），利润率为7.1%（2023年上半年：6.5%）。上半年实现的资产剥离对营业收入产生了轻微的积极影响。基于前景的营业收入1增长了15%，达到8.49亿欧元，利润率为8.9%（2023年上半年：7.9%）。

In Care Delivery, operating income declined by 22% to EUR 521 million (-22% at constant currency), resulting in a margin of 6.9% (H1 2023: 8.8%). Operating income margin on outlook base1 improved to 9.6% (H1 2023: 9.2%). In Care Enablement, operating income strongly increased to EUR 138 million (H1 2023: EUR -23 million), resulting in a margin of 5.2% (H1 2023: -0.9%).

在护理服务方面，营业收入下降了22%，降至5.21亿欧元（按不变货币计算为22%），利润率为6.9%（2023年上半年：8.8%）。基于前景的营业收入利润率1提高至9.6%（2023年上半年：9.2%）。在护理支持方面，营业收入大幅增加至1.38亿欧元（2023年上半年：2300万欧元），利润率为5.2%（2023年上半年：0.9%）。

Operating income margin on outlook base1 improved strongly to 5.5% (H1 2023: 3.1%). Operating income for Corporate amounted to EUR 17 million (H1 2023: -15 million)..

基于前景的营业收入利润率1大幅提高至5.5%（2023年上半年：3.1%）。公司营业收入为1700万欧元（2023年上半年：-1500万欧元）。。

Net income2 increased by 33% to EUR 187 million in the second quarter (+34% at constant currency). Net income on outlook base1 increased by 18%.

第二季度净收入2增长33%，达到1.87亿欧元（按固定货币计算，增长34%）。基于前景1的净收入增长了18%。

In the first half, net income2 increased by 14% to EUR 258 million (+15% at constant currency). Net income on outlook base1 increased by 26%.

上半年，净收入2增加了14%，达到2.58亿欧元（按固定货币计算增加了15%）。基于前景1的净收入增长了26%。

Basic earnings per share (EPS) increased by 33% to EUR 0.64 (+34% at constant currency). EPS on outlook base1 increased by 18% to EUR 0.70.

基本每股收益（EPS）增长33%，达到0.64欧元（按固定货币计算为34%）。基于前景1的每股收益增长18%，至0.70欧元。

In the first half, EPS increased by 14% to EUR 0.88 (+15% at constant currency). EPS on outlook base1 increased by 26% to EUR 1.38 .

上半年，每股收益增长14%，达到0.88欧元（按固定货币计算为15%）。基于前景1的每股收益增长26%，至1.38欧元。

Lower net financial debt and further improved net leverage ratio

降低净金融债务，进一步提高净杠杆率

In the second quarter, Fresenius Medical Care generated EUR 442 million of operating cash flow (Q2 2023: EUR 1,007 million), resulting in a margin of 9.3% (Q2 2023: 20.9%). The operating cash flow development was negatively impacted by EUR 407 million, primarily as a result of changing vendors post the cyber incident at Change Healthcare.

。运营现金流发展受到4.07亿欧元的负面影响，主要是由于Change Healthcare发生网络事件后供应商的变化。

This negative cash impact is expected to be recovered in Q3 2024. Additionally, the phasing of federal income tax payments in the U.S. negatively impacted the development..

这种负面现金影响预计将在2024年第三季度恢复。此外，美国联邦所得税分期支付对发展产生了负面影响。。

In the first half, operating cashflow amounted to EUR 570 million (H1 2023: EUR 1,150 million), resulting in a margin of 6.0% (H1 2023: 12.1%).

上半年，营业现金流为5.7亿欧元（2023年上半年：11.5亿欧元），利润率为6.0%（2023年上半年：12.1%）。

Free cash flow4 amounted to EUR 289 million in the second quarter (Q2 2023: EUR 852 million), resulting in a margin of 6.1% (H1 2023: 17.7%). In the first half, Fresenius Medical Care generated free cash flow of EUR 287 million (H1 2023: EUR 854 million), resulting in a margin of 3.0% (H1 2023: 9.0%)..

第二季度自由现金流4达到2.89亿欧元（2023年第二季度：8.52亿欧元），利润率为6.1%（2023年上半年：17.7%）。上半年，费森尤斯医疗产生了2.87亿欧元的自由现金流（2023年上半年：8.54亿欧元），利润率为3.0%（2023年上半年：9.0%）。。

Total net debt and lease liabilities were further reduced to EUR 10,658 million (Q2 2023: EUR 11,714 million). At 3.1x, the corresponding net leverage ratio (net debt/EBITDA) further decreased towards the lower end of our self-imposed target corridor.

净债务和租赁负债总额进一步减少至106.58亿欧元（2023年第二季度：117.14亿欧元）。相应的净杠杆率（净债务/息税折旧摊销前利润）为3.1倍，朝着我们自我设定的目标走廊的低端进一步下降。

Outlook

展望

Fresenius Medical Care confirms its outlook for fiscal 2024 and expects revenue to grow by a low- to mid-single digit percent rate compared to prior year. The company expects operating income to grow by a mid- to high-teens percent rate compared to prior year.

费森尤斯医疗保健公司证实了其2024财年的前景，预计收入将比上年增长低至中个位数。该公司预计营业收入将比上年增长10%左右。

The expected growth rates for 2024 are at constant currency, excluding special items as well as the business impacts from closed divestitures in 2023 and the settlement agreement with the U.S. government (Tricare) in Q4 2023. The 2023 basis for the revenue outlook is EUR 19,049 million and for the operating income outlook is EUR 1,540 million..

2024年的预期增长率保持不变，不包括特殊项目以及2023年关闭资产剥离和2023年第四季度与美国政府（Tricare）达成的结算协议对业务的影响。2023年收入前景为190.49亿欧元，营业收入前景为1.54亿欧元。。

The company also reconfirms its targets to achieve an operating income margin of 10% to 14% by 2025. This excludes impacts from portfolio changes.

该公司还重申了到2025年实现10%-14%营业收入利润率的目标。这不包括投资组合变化的影响。

Patients, clinics and employees

患者、诊所和员工

As of June 30, 2024, Fresenius Medical Care treated 311,037 patients in 3,757 dialysis clinics worldwide and had 113,639 employees (headcount) globally, compared to 117,128 employees as of March 31, 2024.

截至2024年6月30日，费森尤斯医疗保健公司在全球3757家透析诊所治疗了311037名患者，全球拥有113639名员工（总人数），而截至2024年3月31日，这一数字为117128名员工。

Media conference call

媒体电话会议

Fresenius Medical Care will host a media conference call to discuss the results of the second quarter and first half of 2024 earnings today, July 30, 2024, at 09:30 a.m. CEST / 3:30 a.m. EDT. The media conference call is for journalists who can register vial the following link: Registration. Details on the media conference call are also available here.

费森尤斯医疗保健公司（Fresenius Medical Care）将于今天2024年7月30日上午9:30 CEST/美国东部夏令时凌晨3:30召开媒体电话会议，讨论2024年第二季度和上半年的业绩。媒体电话会议面向记者，他们可以通过以下链接注册：注册。有关媒体电话会议的详细信息也可以在这里找到。

Attendees who would like to follow the presentation parallel to the conference call, you can register here for the webcast. The webcast will only be broadcasted in “listen only” mode..

如果与会者希望在电话会议的同时关注演示文稿，您可以在此处注册网络广播。网络广播将仅以“仅收听”模式播放。。

Investor conference call

投资者电话会议

Fresenius Medical Care will host a conference call to discuss the results of the second quarter and first half of 2024 today, July 30, 2024, at 2:00 p.m. CEST / 8:00 a.m. EDT. Details are available here. A replay will be available shortly after the call.

费森尤斯医疗保健公司（Fresenius Medical Care）将于今天2024年7月30日下午2:00 CEST/美国东部夏令时上午8:00召开电话会议，讨论2024年第二季度和上半年的结果。此处提供详细信息。通话后不久将提供重播。

Please refer to our statement of earnings included at the end of this news and to the attachments as separate PDF files for a complete overview of the results of the second quarter and first half of 2024. Our 6-K disclosure provides more details.

有关2024年第二季度和上半年业绩的完整概述，请参阅本新闻末尾的收益表以及作为单独PDF文件的附件。我们的6K披露提供了更多细节。

1Revenue and operating income outlook, as referred to in the 2024 outlook, are both at constant currency, excluding special items as well as the business impact from closed divestitures in 2023 and the settlement agreement with the U.S. government (Tricare) in Q4 2023. For FY 2023 and 2024, special items include costs related to the FME25 program, the Humacyte remeasurements, the legal form conversion costs and effects from legacy portfolio optimization.

1《2024年展望》中提到的收益和营业收入展望均为固定货币，不包括特殊项目以及2023年关闭资产剥离和2023年第四季度与美国政府（Tricare）达成的结算协议对业务的影响。对于2023财年和2024财年，特殊项目包括与FME25计划相关的成本、Humacyte重新测量、法律形式转换成本以及遗留投资组合优化的影响。

For further details please see the reconciliation attached to the Press Release..

有关更多详细信息，请参阅新闻稿所附的对帐。。

2Net income attributable to shareholders of Fresenius Medical Care AG

2归属于费森尤斯医疗保健公司股东的净收入

3The company transfers products between segments at fair market value. The associated internal revenues and expenses and all other consolidation of transactions are included within “Inter-segment eliminations”.

3公司以公平的市场价值在不同部门之间转让产品。相关的内部收入和支出以及所有其他合并交易均包含在“部门间抵销”中。

4Net cash provided by / used in operating activities, after capital expenditures, before acquisitions/divestitures, investments, and dividends

4资本支出后、收购/资产剥离、投资和股息前，经营活动提供/使用的现金净额